Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711756 | 1.00 | GNPAT (0.60) | GNPATOPRK1OPRM1ERAP2LNPEP | |
| SCHEMBL1711761 | 1.00 | GNPAT (0.60) | GNPATOPRK1OPRM1ERAP2LNPEP | |
| SCHEMBL2108121 | 1.00 | GNPAT (0.60) | GNPATOPRK1OPRM1ERAP2LNPEP | |
| SCHEMBL8170666 | 0.96 | GNPAT (0.58) | GNPATOPRK1OPRM1ERAP2LNPEP | |
| SCHEMBL31181294 | 0.96 | GNPAT (0.55) | GNPATOPRK1OPRM1ERAP2LNPEP | |
| SCHEMBL31181267 | 0.96 | GNPAT (0.55) | GNPATOPRK1OPRM1ERAP2LNPEP | |
| SCHEMBL31181210 | 0.95 | GNPAT (0.54) | GNPATOPRK1OPRM1ERAP2LNPEP | |
| SCHEMBL29496448 | 0.94 | GNPAT (0.53) | GNPATOPRK1OPRM1ECE1 | |
| SCHEMBL30385347 | 0.94 | GNPAT (0.53) | GNPATOPRK1OPRM1ECE1 | |
| SCHEMBL30198611 | 0.94 | BACE1 (0.55) | GNPATOPRK1OPRM1ERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
| EP-1370298-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | Syntarga B.V. (NL) | 2003-12-17 | — | — | EP | claimed |
| WO-2002083180-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA B.V. (NL) | 2002-10-24 | — | — | WO | claimed |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | BYONDIS B.V. (NL) | 2022-08-23 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| CN-106749665-B | Conjugates of CC-1065 analogs and bifunctional linkers | 辛塔佳有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS B.V. (NL) | 2020-09-24 | — | — | US | disclosed |
| EP-3525826-B1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS BV (NL) | 2020-07-22 | — | — | EP | disclosed |
| EP-3108886-B1 | CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | SYNTARGA BV (NL) | 2020-06-17 | — | — | EP | disclosed |
| EP-3525826-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | Synthon Biopharmaceuticals B.V. (NL) | 2019-08-21 | — | — | EP | disclosed |
| EP-1909846-B1 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES COMPRISING THE SAME AND PROCESSES FOR THEIR PREPARATION | SYNTARGA BV (NL) | 2018-12-26 | — | — | EP | disclosed |
| EP-2173739-B1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA BV (NL) | 2013-07-31 | — | — | EP | disclosed |
| CN-103118679-A | Novel conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV | 2013-05-22 | — | — | CN | disclosed |
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | SYNTARGA B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| EP-1370298-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | Syntarga B.V. (NL) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002083180-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA B.V. (NL) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | GNPAT 1927/4885OPRK1 2629/4885OPRM1 3942/4885 |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | DLST, ADSL, LANCL1 | GNPAT 1411/4885OPRK1 3821/4885OPRM1 4169/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | GNPAT 2453/4885OPRK1 4335/4885OPRM1 4659/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | GNPAT 1698/4885OPRK1 2745/4885OPRM1 3850/4885 |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | PCNA, TOP1, TOP2B | GNPAT 1256/4885OPRK1 2947/4885OPRM1 4151/4885 |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | DLST, ADSL, LANCL1 | GNPAT 1411/4885OPRK1 3821/4885OPRM1 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.